Invokana reduces the risk of major CV events over the long term (6.5 years).1
CANVAS showed a 14% relative reduction in risk for MACE among a mix of both primary and secondary prevention patients compared to placebo. HR: 0.86 (95% CI, 0.75-0.97)1 ARR: 4.6 fewer events per 1000 patient-years.1
All-cause mortality was the first secondary endpoint in the pre-specified hypothesis testing sequence.1
Because analysis of this endpoint failed to show superiority for Invokana, hypothesis testing could not be carried out for the other secondary endpoints.1
CANVAS also showed a 33% relative reduction in risk of hospitalisation for heart failure among a mix of both primary and secondary prevention patients compared to placebo. HR: 0.67 (95% CI, 0.52-0.87)1 ARR: 3.2 fewer events per 1000 patient-years.1
ARR: Absolute Risk Reduction; CANVAS: Canagliflozin Cardiovascular Assessment Study; CI: Confidence Interval; CV: Cardiovascular; HHF: Hospitalisation for Heart Failure; HR: Hazard Ratio; MACE: Major Adverse Cardiovascular Events; SoC: Standard of Care; T2DM: Type 2 Diabetes Mellitus.
- Neal B, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(7):644–657. doi: 10.1056/NEJMoa1611925.
- Invokana Summary of Product Characteristics. Napp Pharmaceuticals Limited. Available at: https://www.medicines.org.uk/emc/product/8855/smpc and https://www.medicines.org.uk/emc/medicine/28400#gref [Accessed December 2021].